Global Alliance for TB Drug Development
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.tballiance.org
Clinical Trials
32
Active:1
Completed:29
Trial Phases
4 Phases
Phase 1:15
Phase 2:11
Phase 3:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (48.4%)Phase 2
11 (35.5%)Phase 3
4 (12.9%)Not Applicable
1 (3.2%)Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
Phase 2
Active, not recruiting
- Conditions
- Pulmonary TBPulmonary TuberculosisDrug Sensitive Tuberculosis
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 300
- Registration Number
- NCT06058299
- Locations
- 🇵🇭
Care Clinical Trial Group Inc., Dasmariñas, Philippines
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇵🇭Tropical Disease Foundation, Makati City, Philippines
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Phase 1
Completed
- Conditions
- Multi Drug Resistant TuberculosisDrug Sensitive TuberculosisPulmonary DiseaseDrug-resistant TuberculosisMycobacterium Tuberculosis InfectionTuberculosis, PulmonaryTuberculosis
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT05526911
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 106
- Registration Number
- NCT04890535
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
Phase 1
Completed
- Conditions
- TuberculosisTuberculosis, Pulmonary
- Interventions
- Drug: TBI-223 PlaceboDrug: TBI-223 1800 mgDrug: TBI-223 2400mg
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT04865536
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
Phase 1
Completed
- Conditions
- Pulmonary DiseaseDrug-resistant TuberculosisTuberculosis, PulmonaryTuberculosisMulti Drug Resistant TuberculosisDrug Sensitive TuberculosisMycobacterium Tuberculosis Infection
- Interventions
- Drug: TBAJ-876 suspensionDrug: Placebo suspensionDrug: TBAJ-876 100 mg tabletDrug: TBAJ-876 25 mg tablet
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 137
- Registration Number
- NCT04493671
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found